Pneumococcal vaccine in patients with systemic juvenile idiopathic arthritis receiving biologic therapy: International practice review

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

International practice of immunization against pneumococcus in patients with systemic juvenile idiopathic arthritis (SJIA) receiving biological therapy is generalized in this review. High efficiency and safety of pneumococcal vaccines in children with SJIA is presented. Numerous researches show the adequate immune response after vaccination as well as alongside with genetically engineered biologic drugs therapy. Prevention of pneumococcal disease in patients with SJIA reduces the risk of development of pneumococcal diseases severe complications.

Cite

CITATION STYLE

APA

Alekseeva, E. I., Van’kova, D. D., Soloshenko, M. A., Dvoryakovskaya, T. M., Isaeva, K. B., Denisova, R. V., … Tkachenko, N. E. (2019). Pneumococcal vaccine in patients with systemic juvenile idiopathic arthritis receiving biologic therapy: International practice review. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 18(2), 101–108. https://doi.org/10.15690/vsp.v18i2.2012

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free